254 related articles for article (PubMed ID: 11681716)
1. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats.
Marzban L; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):147-57. PubMed ID: 11681716
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle.
Mohammad A; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):103-8. PubMed ID: 11681710
[TBL] [Abstract][Full Text] [Related]
3. Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
Bhanot S; Girn J; Poucheret P; McNeill JH
Mol Cell Biochem; 1999 Dec; 202(1-2):131-40. PubMed ID: 10706003
[TBL] [Abstract][Full Text] [Related]
4. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.
Mohammad A; Wang J; McNeill JH
Mol Cell Biochem; 2002 Jan; 229(1-2):125-8. PubMed ID: 11936837
[TBL] [Abstract][Full Text] [Related]
5. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
6. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats.
Yuen VG; Vera E; Battell ML; Li WM; McNeill JH
Diabetes Res Clin Pract; 1999 Jan; 43(1):9-19. PubMed ID: 10199584
[TBL] [Abstract][Full Text] [Related]
7. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase B in the diabetic heart.
Huisamen B
Mol Cell Biochem; 2003 Jul; 249(1-2):31-8. PubMed ID: 12956395
[TBL] [Abstract][Full Text] [Related]
11. The effects of insulin and beta-adrenergic stimulation on glucose transport, glut 4 and PKB activation in the myocardium of lean and obese non-insulin dependent diabetes mellitus rats.
Huisamen B; van Zyl M; Keyser A; Lochner A
Mol Cell Biochem; 2001 Jul; 223(1-2):15-25. PubMed ID: 11681717
[TBL] [Abstract][Full Text] [Related]
12. Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
Shinde UA; Mehta AA; Goyal RK
Indian J Exp Biol; 2001 Sep; 39(9):864-70. PubMed ID: 11831366
[TBL] [Abstract][Full Text] [Related]
13. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
Yuen VG; Orvig C; McNeill JH
Am J Physiol; 1997 Jan; 272(1 Pt 1):E30-5. PubMed ID: 9038848
[TBL] [Abstract][Full Text] [Related]
14. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
Dabroś W; Dziga D; Kordowiak AM
Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
[TBL] [Abstract][Full Text] [Related]
15. Effect of vanadium on insulin sensitivity and appetite.
Wang J; Yuen VG; McNeill JH
Metabolism; 2001 Jun; 50(6):667-73. PubMed ID: 11398143
[TBL] [Abstract][Full Text] [Related]
16. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
[TBL] [Abstract][Full Text] [Related]
17. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; Thompson KH; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):270-6. PubMed ID: 8402391
[TBL] [Abstract][Full Text] [Related]
18. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
19. Contrasting insulin dose-dependent defects in activation of atypical protein kinase C and protein kinase B/Akt in muscles of obese diabetic humans.
Casaubon L; Sajan MP; Rivas J; Powe JL; Standaert ML; Farese RV
Diabetologia; 2006 Dec; 49(12):3000-8. PubMed ID: 17028898
[TBL] [Abstract][Full Text] [Related]
20. Exercise training attenuated the PKB and GSK-3 dephosphorylation in the myocardium of ZDF rats.
Lajoie C; Calderone A; Trudeau F; Lavoie N; Massicotte G; Gagnon S; Béliveau L
J Appl Physiol (1985); 2004 May; 96(5):1606-12. PubMed ID: 14698990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
